How to buy Sol Gel Technologies stock (SLGL)

Sol Gel Technologies is a biotechnology business based in the US. Sol Gel Technologies shares (SLGL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.44 – a decrease of 8.2% over the previous week. Sol Gel Technologies employs 36 staff and has a trailing 12-month revenue of around $6.6 million.

Our top picks for where to buy Sol Gel Technologies stock

Buy Sol Gel Technologies stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Sol Gel Technologies stock price (NASDAQ: SLGL)

Use our graph to track the performance of SLGL stocks over time.

Sol Gel Technologies shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$0.44
52-week range	$0.33 - $1.58
50-day moving average more info button	$0.57
200-day moving average more info button	$0.72
Wall St. target price	$5.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.34

Is it a good time to buy Sol Gel Technologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sol Gel Technologies price performance over time

Historical closes compared with the close of $0.4409 from 2024-12-18

1 week (2024-12-13)	-8.05%
1 month (2024-11-20)	-0.02%
3 months (2024-09-20)	-38.76%
6 months (2024-06-20)	-51.98%

1 year (2023-12-20)	-64.73%
2 years (2022-12-20)	-89.67%
3 years (2021-12-20)	6.99
5 years (2019-12-20)	9.39

Sol Gel Technologies financials

Revenue TTM	$6.6 million
Operating margin TTM	29.89%
Gross profit TTM	$-8,799,000
Return on assets TTM	-21.63%
Return on equity TTM	-35.85%
Profit margin	-227.4%
Book value	$1.39
Market Capitalization more info button	$12.3 million

TTM: trailing 12 months

Sol Gel Technologies share dividends

We're not expecting Sol Gel Technologies to pay a dividend over the next 12 months.

Sol Gel Technologies share price volatility

Over the last 12 months, Sol Gel Technologies's shares have ranged in value from as little as $0.334 up to $1.5754. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sol Gel Technologies's is 1.603. This would suggest that Sol Gel Technologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sol Gel Technologies overview

Sol-Gel Technologies Ltd. , together with its subsidiary Sol-Gel Technologies Inc. , develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc.

Frequently asked questions

What percentage of Sol Gel Technologies is owned by insiders or institutions?
Currently 65.169% of Sol Gel Technologies shares are held by insiders and 19.355% by institutions. How many people work for Sol Gel Technologies?
Latest data suggests 36 work at Sol Gel Technologies. When does the fiscal year end for Sol Gel Technologies?
Sol Gel Technologies's fiscal year ends in December. Where is Sol Gel Technologies based?
Sol Gel Technologies's address is: 7 Golda Meir Street, Ness Ziona, Israel, 7403650 What is Sol Gel Technologies's ISIN number?
Sol Gel Technologies's international securities identification number is: IL0011417206 What is Sol Gel Technologies's CUSIP number?
Sol Gel Technologies's Committee on Uniform Securities Identification Procedures number is: M8694L103